What are the drug interactions between atomoxetine and bupropion (Wellbutrin)?

Significant Drug Interaction: Bupropion Substantially Increases Atomoxetine Levels

When atomoxetine and bupropion (Wellbutrin) are combined, atomoxetine blood levels increase approximately 5-fold, while its active metabolite decreases by 1.5-fold, creating a clinically significant drug-drug interaction that requires dose adjustment or alternative therapy 1.

Mechanism of Interaction

Both bupropion and atomoxetine are metabolized through the CYP2D6 enzyme system. Bupropion and its metabolites are potent CYP2D6 inhibitors 2. When bupropion inhibits CYP2D6, atomoxetine cannot be properly metabolized, leading to:

• 5.1-fold increase in atomoxetine systemic exposure (AUC)
• 1.7-fold increase in peak atomoxetine levels (Cmax: 226 to 386 ng/mL)
• Prolonged atomoxetine half-life
• Decreased formation of the active metabolite 4-hydroxyatomoxetine-O-glucuronide 1

This interaction persists for at least 7 days after the last bupropion dose 2.

Clinical Implications and Risks

The dramatically elevated atomoxetine levels increase the risk of:

• Cardiovascular effects: Increased heart rate and blood pressure (atomoxetine already causes mild HR/BP increases) 3
• Gastrointestinal symptoms: Nausea, vomiting, particularly severe
• CNS effects: Excessive somnolence, agitation
• Suicidal ideation: Atomoxetine carries an FDA black box warning for increased suicidal thoughts 3
• Rare but serious: Hepatotoxicity risk 3

Management Recommendations

If this combination is clinically necessary:

1. Reduce atomoxetine dose substantially - The FDA label for bupropion explicitly states that when coadministered with CYP2D6 substrates, "it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index" 2

2. Start with 25-50% of the usual atomoxetine dose and titrate cautiously based on clinical response and tolerability

3. Monitor cardiovascular parameters closely: Obtain baseline and serial heart rate and blood pressure measurements 3

4. Watch for CNS toxicity: The combination of dopaminergic effects from both medications may cause restlessness, agitation, tremor, or other CNS symptoms 2

5. Screen for suicidal ideation more frequently given atomoxetine's black box warning 3

Alternative Approaches

Consider these safer alternatives:

• Use stimulant medications instead of atomoxetine if treating ADHD, as stimulants are first-line therapy and don't share this interaction 3, 4
• Use alternative antidepressants with minimal CYP2D6 inhibition (avoid fluoxetine, paroxetine, duloxetine which are also potent CYP2D6 inhibitors) 5, 6
• Use guanfacine or clonidine as alternative non-stimulant ADHD medications if stimulants are contraindicated 3, 4

Critical Pitfalls to Avoid

• Don't assume standard atomoxetine dosing is safe - the 5-fold exposure increase is substantial and clinically meaningful 1
• Don't overlook the prolonged effect - bupropion's CYP2D6 inhibition persists for at least 7 days after discontinuation 2
• Don't combine with other CYP2D6 substrates - bupropion affects multiple medications metabolized by this pathway including certain beta-blockers, antipsychotics, and other antidepressants 2, 5, 6
• Be aware of additive dopaminergic effects - both medications have dopamine activity which can cause cumulative CNS toxicity 2